PsilodexMedication × psilocybin
Your list , 0 items
Medication class

Antidepressants and psilocybin.

44 records in this group. 20 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

44Records
20With human data

Overview

Reviewed 2026-10-14

Antidepressants act on serotonin in different ways, and the published data differ with them. In an online survey, reports from people taking SSRIs or SNRIs described weaker-than-expected psilocybin effects more often than reports from people taking bupropion, which does not act directly on serotonin (47–55% vs 29%; Gukasyan 2023). Drugs that block 5-HT2A, the serotonin receptor psilocybin acts on, such as trazodone and mirtazapine, are expected to blunt its effects (Bonson 1996; Halman 2024).

With LSD, long-term tricyclic use intensified the response, while long-term use of phenelzine, an MAO inhibitor, nearly abolished it in 2 people (Bonson & Murphy 1996). One case report describes a hypertensive emergency after psilocybin mushrooms were taken with tranylcypromine, another MAO inhibitor, and extended-release dextroamphetamine-amphetamine; the authors attributed it to phenylethylamine in the mushrooms (Barnett 2024). In a small open-label trial of inhaled DMT that was not designed to compare groups, participants taking antidepressants had adverse events similar to those not taking them (Falchi-Carvalho 2025, as summarized in Tap 2025).

Stopping an antidepressant, especially suddenly, can cause withdrawal (discontinuation) symptoms or a return of depression (Zoloft prescribing information). Most psilocybin trials required stopping antidepressants before enrollment; one gave psilocybin alongside a continued SSRI (Tap 2025; Goodwin 2023). Later analyses of trial data differ on whether stopping changes the response (Erritzoe 2024; Marwood 2024).

Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.

Sources for this overview
  1. Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716.
  2. Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
  3. Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
  4. Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233.
  5. Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
  6. Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 2025;50(6):895–903.
  7. Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
  8. Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499.
  9. Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38(5):458–470.
  10. Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res 2024;180:198–203.
  11. Zoloft (sertraline) prescribing information, sections 2 and 14 (DailyMed)

Also searched as antidepressant · depression medication · depression medicine · anti-depressant

01 What the evidence covers

Best evidence available per medication
2Controlled trial
5Open-label trial
6Case reports
Case reports or online surveys
7Other psychedelic
Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text
24No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • Agomelatine · ValdoxanEvidence: No psilocybin data

    Psychotropics

    It may slightly change psilocybin's effects but does not block the receptor psilocybin works through. Also, its label warns of liver damage.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Amitriptyline · ElavilEvidence: No psilocybin data

    Depression

    Not studied with psilocybin; related drugs strengthened LSD's effects. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Amoxapine · AsendinEvidence: No psilocybin data

    Depression, including depression with anxiety or agitation

    It blocks the receptor psilocybin works through, so it may weaken psilocybin, though related drugs strengthened LSD's effects.

    CO: unsettled · OR: not mentioned in rule · NM: rules not final

  • Brexanolone · ZulressoEvidence: No psilocybin data

    Psychotropics

    Not studied with psilocybin. Also, the infusion causes sedation and loss of consciousness, and the product is no longer marketed.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Bupropion · Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XLEvidence: Case reports

    Depression (major depressive disorder); Seasonal affective disorder (prevention of seasonal depression; Wellbutrin XL, Aplenzin)

    In a survey, bupropion takers less often reported weaker psilocybin effects than SSRI or SNRI takers. Also, it raises seizure risk and blood pressure.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Citalopram · CelexaEvidence: Open-label trial

    Depression (major depressive disorder)

    SSRIs often weakened psilocybin's effects in real-world reports; one trial found effects largely kept. Serotonin syndrome is unlikely, not impossible. Stopping suddenly can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Clomipramine · AnafranilEvidence: Other psychedelic

    Obsessive-compulsive disorder (OCD)

    It may weaken psilocybin, yet 5 people on it or related drugs had stronger LSD responses. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Desipramine · NorpraminEvidence: Other psychedelic

    Depression

    Its effect on psilocybin is unknown; with LSD, all 5 people on such antidepressants had stronger responses. Also, it raises blood pressure and heart rate.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Desvenlafaxine · PristiqEvidence: Other psychedelic

    Major depressive disorder (depression) in adults

    It is expected to weaken psilocybin and may add to its blood pressure rise; serotonin syndrome is considered unlikely, though not impossible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Dextromethorphan–bupropion · AuvelityEvidence: No psilocybin data

    Major depressive disorder (MDD) in adults; Agitation from Alzheimer's dementia

    Its dextromethorphan boosts serotonin and causes dissociation, which may add to psilocybin's effects. Also, bupropion can make seizures more likely and raise blood pressure.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Dothiepin / dosulepin · ProthiadenEvidence: No psilocybin data

    Psychotropics

    With LSD, long-term tricyclic use strengthened responses, so it may strengthen psilocybin (not studied). Also, it carries heart-rhythm and seizure risks.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Doxepin · Sinequan, SilenorEvidence: No psilocybin data

    Depression; Anxiety

    In theory it blunts psilocybin, but related tricyclics strengthened LSD responses. Also, it sedates and affects heart rhythm; 3–6 mg acts mainly as an antihistamine.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Duloxetine · Cymbalta, Drizalma SprinkleEvidence: Case reports

    Depression (major depressive disorder); Generalized anxiety disorder

    In one case, psilocybin with duloxetine was well tolerated except mild headache; blood pressure rose. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Escitalopram · LexaproEvidence: Controlled trial

    Depression (major depressive disorder); Generalized anxiety disorder

    In one controlled study, escitalopram kept psilocybin's positive mood effects and reduced anxiety and blood pressure rises. Stopping it suddenly can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Esketamine · SpravatoEvidence: No psilocybin data

    Treatment-resistant depression in adults; Depressive symptoms in adults with major depression and acute suicidal thoughts or behavior

    Not studied with psilocybin; it causes dissociation and raises blood pressure, so added effects are possible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Fluoxetine · Prozac, SarafemEvidence: Open-label trial

    Depression (major depressive disorder); Obsessive-compulsive disorder (OCD)

    Antidepressants like this often made psilocybin feel weaker in real-world reports, and fluoxetine lingers for weeks. Stopping it suddenly after regular use can cause relapse.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Fluvoxamine · LuvoxEvidence: No psilocybin data

    Obsessive-compulsive disorder (OCD)

    SSRIs often made psilocybin feel weaker in real-world reports; fluvoxamine may also slow how the body clears psilocybin.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Gepirone · ExxuaEvidence: No psilocybin data

    Major depressive disorder (MDD) in adults

    Like buspirone, which reduced psilocybin's visual effects, it activates a serotonin receptor, so it is expected to dampen those effects.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Imipramine · TofranilEvidence: Other psychedelic

    Depression; Bedwetting in children (short-term add-on)

    Its effect on psilocybin is unclear; with LSD, it or similar drugs increased the response in all 5 people interviewed.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Isocarboxazid · MarplanEvidence: Other psychedelic

    Depression

    It reduced LSD's effects in a small study; it is unstudied with psilocybin, and blood pressure changes with the combination are possible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Levomilnacipran · FetzimaEvidence: No psilocybin data

    Major depressive disorder (MDD) in adults

    It is expected to make psilocybin feel weaker, as SNRIs did in a survey; its heart rate and blood pressure rise may add to psilocybin's.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Lofepramine · GamanilEvidence: No psilocybin data

    Psychotropics

    In a small LSD study, related tricyclics increased the response, so it may strengthen psilocybin. Also, it can affect heart rhythm and lower seizure threshold.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Maprotiline · LudiomilEvidence: No psilocybin data

    Depression (major depressive disorder and dysthymia); Anxiety that comes with depression

    Related antidepressants increased the LSD response, so psilocybin's effects may be stronger. Also, it can make seizures more likely and affect heart rhythm.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Mianserin · TolvonEvidence: No psilocybin data

    Psychotropics

    It blocks the receptor psilocybin works through, so it may weaken psilocybin's effects. Also, it lowers seizure threshold and can trigger hypomania in bipolar illness.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Milnacipran · SavellaEvidence: No psilocybin data

    Fibromyalgia

    In a survey, people on related drugs reported weaker psilocybin effects, so it is expected to weaken psilocybin and may add to its heart-rate rise.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Mirtazapine · RemeronEvidence: No psilocybin data

    Depression

    It blocks the receptor psilocybin works through, so it may weaken psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Moclobemide · ManerixEvidence: No psilocybin data

    Psychotropics

    In people, related drugs weakened psychedelic effects and raised psilocybin's blood pressure effect, so it is expected to do the same.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • NefazodoneEvidence: No psilocybin data

    Depression

    It blocks the receptor psilocybin works through, so it may weaken psilocybin's effects. Also, it can cause serious, sometimes fatal, liver injury.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Nortriptyline · PamelorEvidence: Case reports

    Depression

    In one case, psilocybin had no noticeable effect when taken with nortriptyline plus phenelzine. Also, it can affect heart rhythm and seizure threshold.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Olanzapine–fluoxetine · SymbyaxEvidence: Other psychedelic

    Bipolar depression (bipolar I); Treatment-resistant depression

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Paroxetine · Paxil, Pexeva, BrisdelleEvidence: Open-label trial

    Depression; Obsessive-compulsive disorder (OCD)

    SSRIs like paroxetine often made psilocybin feel weaker; serotonin syndrome is considered unlikely, not impossible. Stopping it suddenly can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Phenelzine · NardilEvidence: Case reports

    Depression (particularly atypical depression)

    Its label contraindicates use with serotonergic drugs, a class that includes psilocybin; in one case, psilocybin mushrooms had no noticeable effect.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Protriptyline · VivactilEvidence: No psilocybin data

    Depression

    Related tricyclic drugs increased LSD's effects, so it is expected to intensify psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Reboxetine · EdronaxEvidence: No psilocybin data

    Psychotropics

    Its rise in blood pressure and heart rate may add to psilocybin's; it is not expected to weaken psilocybin.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Selegiline · Eldepryl, Emsam, ZelaparEvidence: No psilocybin data

    Parkinson's disease (add-on to levodopa/carbidopa); Major depressive disorder in adults (Emsam patch)

    Not studied with psilocybin; usual oral doses mainly block one enzyme (MAO-B), but the patch or higher doses may raise psilocybin levels and blood pressure.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Sertraline · ZoloftEvidence: Open-label trial

    Depression (major depressive disorder); Obsessive-compulsive disorder (OCD)

    SSRIs like sertraline often made psilocybin feel weaker; serotonin syndrome is considered unlikely, not impossible. Stopping it suddenly can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Tianeptine · StablonEvidence: No psilocybin data

    Anxiety (promoted; not FDA-approved); Depression (promoted; not FDA-approved)

    Not studied with psilocybin; its serotonin effect is unclear. Also, it acts on opioid receptors, with misuse and dependence potential.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Tranylcypromine · ParnateEvidence: Controlled trial

    Depression in adults not responding to other antidepressants

    Its label contraindicates use with serotonergic drugs, a class that includes psilocybin; in one small 1968 study, it increased psilocybin's blood pressure rise.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Trazodone · Desyrel, OleptroEvidence: Case reports

    Depression (major depressive disorder)

    In one case, nightly trazodone blocked psilocybin's psychedelic effects; it blocks the receptor psilocybin works through. Also, it can affect heart rhythm and blood pressure.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Trimipramine · SurmontilEvidence: No psilocybin data

    Depression

    In lab studies it binds strongly to psilocybin's receptor, so it may weaken psilocybin. Also, it can affect heart rhythm and seizure risk.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Venlafaxine · Effexor XREvidence: Other psychedelic

    Depression (major depressive disorder); Generalized anxiety disorder (GAD; extended-release)

    It is expected to make psilocybin feel weaker, as SSRIs do, and higher doses may add to psilocybin's blood pressure rise.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Vilazodone · ViibrydEvidence: Open-label trial

    Major depressive disorder (adults)

    It acts on serotonin and may make psilocybin feel weaker, as SSRIs do. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Vortioxetine · TrintellixEvidence: Case reports

    Major depressive disorder (adults)

    In one case, psilocybin during vortioxetine (with duloxetine) was well tolerated with a modest blood pressure rise. Related antidepressants were linked to weaker psilocybin effects.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Zuranolone · ZurzuvaeEvidence: No psilocybin data

    Postpartum depression (adults)

    Its sedation may add to psilocybin's effects (not studied). Also, its label warns of impaired driving for at least 12 hours after each dose.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
41Psychiatric reactions
33Serotonergic
33Withdrawal or rebound if stopped abruptly
31Lowers seizure threshold or carries seizure risk
21Dehydration or electrolyte risk
20Lowers blood pressure or causes orthostasis
20QT-prolonging
20Raises blood pressure or heart rate
18Sedating or CNS depressant
13Anticholinergic
8Blocks 5-HT2A (may blunt effects)
5Liver injury
5MAO inhibition
2Dissociative (NMDA antagonist)
1Hypoglycemia risk
1Opioid

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

1 of 44 named by a provision. 1 unsettled.

Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” and does not limit this by indication or dose. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).

Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” without defining the term or limiting it by indication, so whether it covers this medication is unsettled; the regulator has not addressed this. Amoxapine is an antidepressant approved for depression, but it and its metabolites block dopamine D2 receptors, as antipsychotics do, and its label describes neuroleptic malignant syndrome and tardive dyskinesia. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent.

Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 42 of the 44 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
21Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
15Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233.
14Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499.
14Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716.
13Chisamore N, Kaczmarek ES, Doyle Z, et al. Comparing antidepressant effects of psilocybin-assisted psychotherapy in individuals unmedicated at screening versus individuals discontinuing medications. Can J Psychiatry 2025;70(10):759–767.
13Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38(5):458–470.
13Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res 2024;180:198–203.
13Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
8Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
7Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 2025;50(6):895–903.
7Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689.
6Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
6Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
6Sakai K, Bradley ER, Zamaria JA, et al. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. Psychopharmacology 2024;241(8):1617–1630.
5Chen J, Wang Z, Yong CY, et al. Elucidating the Phase I metabolism of psilocin in vitro. Arch Toxicol 2025;99(3):1085–1094.
2Do A, Michaud V, Stephan JF, et al. Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report. Front Psychiatry 2024;15:1394962.
2Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22(6):603–620.
1Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment. Clin Pharmacol Ther 2022;111(4):886–895.
1Becker AM, Humbert-Droz M, Mueller L, et al. Acute effects and pharmacokinetics of LSD after paroxetine or placebo pre-administration in a randomized, double-blind, cross-over phase I trial. Clin Pharmacol Ther 2025;117(6):1784–1792.
1Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 2016;26:756–766.
1Resnick O, Krus DM, Raskin M. LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci 1964;3:1207–1214.
1Rosenblat JD, et al. Antidepressant effects of psilocybin in the absence of psychedelic effects. Am J Psychiatry 2023 (letter).
1Vojtěchovský M, Hort V, Šafratová V. Influence of MAO inhibitors on psilocybine induced psychosis. Activitas Nervosa Superior 1968;10(3):278–279 (via Tap 2025).

Related classes

Records reviewed 2026-10-14 to 2026-10-25. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25